PROTECTIVE EFFECT OF SAPONIN OF MOMORDICA CYMBALARIA FENZL ON HIGH-GLUCOSE INDUCED NEUROPATHY IN NB-41A3 MOUSE NEUROBLASTOMA CELLS
Objective: The natural product Momordica cymbalaria Fenzl has been in use considerably because of its antidiabetic activity. In this work, we have investigated the protective action of one of its phytoconstituent, a saponin, in peripheral neuropathyâ€“a diabetic complication.
Methods: The saponin was isolated and identified by preparative high-performance liquid chromatography (preparative HPLC) and thin layer chromatography TLC). High glucose (56 mM)-mediated neuropathy was induced in NB-41A3 mouse neuroblastoma cells and the neuroprotective activity of the saponin was assessed by evaluating its effect on the two polyol pathway enzymesâ€“aldose reductase (AR) and sorbitol dehydrogenase (SDH). The accumulation of intracellular sorbitol, activity of Na+K+-ATPase and production of pro-inflammatory cytokines IL-6, IL-1Î² and TNF-Î± were also investigated.
Results: The results showed a significant reduction in AR activity and intracellular accumulation of sorbitol on saponin treatment. Improvement in Na+K+-ATPase activity was evident with a noteworthy reduction in IL-6, IL-1Î² and TNF-Î± production.
Conclusion: These results suggest that the saponin possesses neuroprotective activity in diabetic peripheral neuropathy.
Keywords: Diabetic peripheral neuropathy (DPN), Saponin of Momordica cymbalaria (SMC), Neuroblastoma cells, Aldose reductase, Sorbitol dehydrogenase, Na+K+-ATPase
2. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000;47:123-8.
3. Gabbay KH. The sorbitol pathway and the complications of diabetes. N Engl J Med 1973;288:831-6.
4. Greene DA, Sima AA, Stevens MJ, Feldman EL, Killen PD, Henry DN, et al. Aldose reductase inhibitors: an approach to the treatment of diabetic nerve damage. Diabetes Metab Rev 1993;9:189â€“217.
5. Cameron NE, Cotter MA, Basso M, Hohman TC. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1997;40:271â€“81.
6. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315â€“21.
7. Yagihashi S. Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes Metab Rev 1995;11:193â€“225.
8. Gabbay KH, Merola LO, Field RA. Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes. Science 1966;151:209-10.
9. Kinoshita JH, Nishimura C. The involvement of aldose reductase in diabetic complications. Diabetes Metab Rev 1988;4:323-37.
10. Oates PJ, Mylari BL. Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opin Invest Drugs 1999;8:2095-19.
11. Yasunari K, Kohno M, Kano H, Yokokawa K, Horio T, Yoshikawa J. Aldose reductase inhibitor prevents hyperproliferation and hypertrophy of cultured rat vascular smooth muscle cells induced by high glucose. Arterioscler Thromb Vasc Biol 1995;15:2207â€“12.
12. Tawata M, Ohtaka M, Hosaka Y, Onaya T. Aldose reductase mRNA expression and its activity are induced by glucose in fetal rat aortic smooth muscle (A10) cells. Life Sci 1992;51:719â€“26.
13. Scarpini E, Bianchi R, Moggio M, Sciacco M, Fiori MG, Scarlato G. Decrease of nerve Na+-K+ATPase activity in the pathogenesis of human diabetic neuropathy. J Neurol Sci 1993;120:159-67.
14. Ho E, Bray TM. Antioxidants, NF kappa B activation, and diabetogenesis. Proc Soc Exp Biol Med 1999;222:205â€“13.
15. Koneri RB, Samaddar S, Ramaiah CT. Antidiabetic activity of a triterpenoid saponin isolated from Momordica cymbalaria Fenzl. Indian J Exp Biol 2014;52:46-52.
16. Firdous M, Koneri R, Sarvaraidu CH, Harish M, Shubhapriya KH. NIDDM antidiabetic activity of saponins of Momordica cymbalaria in streptozotocin-nicotinamide NIDDM mice. J Clin Diagn Res 2009;3:1460-5.
17. Freshney Ian R. Cytotoxicity Culture of animal cells: A manual of basic technique. 2nd edn. John Wiley and Sons, Inc; 2005.
18. Patel DK, Kumar R, Sairam K, Hemalatha S. Aldose reductase inhibitory activity of alcoholic extract of Pedalium murex Linn fruit. Asian Pac J Trop Biomed 2012;2: S265-S69.
19. Gerlach U, Hiby W. Methods of enzymatic analysis. 2nd edn. Vol. II. Academic Press: Inc., New York; 1974.
20. Frieler RA, Mitteness DJ, Golovko MY, Gienger HM, Rosenberger TA. Quantitative determination of free glycerol and myoinositol from plasma and tissue by high-performance liquid chromatography. J Chromatogr B: Anal Technol Biomed Life Sci 2009;877:3667-72.
21. Reinila M, MacDonald E, Salem N. Standardized method for the determination of human erythrocyte membrane adenosine triphosphatase. Anal Biochem 1982;124:19â€“26.
22. Inada H, Shindo H, Tawata M, Onaya T. cAMP regulates nitric oxide production and ouabain-sensitive Na+, K+-ATPase activity in SH-SY5Y human neuroblastoma cells. Diabetologia 1998;41:1451-8.
23. Brown MJ, Asbury AK. Diabetic neuropathy. Ann Neurol 1984;15:2-12.
24. Eliasson SG. Nerve conduction changes in experimental diabetes. J Clin Invest 1964;43:2353â€“8.
25. Greene DA, De Jesus PV Jr, Winegrad AI. Effects of insulin and dietary myo-inositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. J Clin Invest 1975;55:1326â€“36.
26. Tomlinson DR, Holmes PR, Mayer JH. Reversal, by treatment with an aldose reductase inhibitor, of impaired axonal transport and motor nerve conduction velocity in experimental diabetes mellitus. Neurosci Lett 1982;31:189â€“93.
27. Koneri R, Balaraman R. Antidiabetic mechanisms of Saponins of Momordica cymbalaria. Pharmacogn Mag 2008;4:197-206.
28. Rao BK, Kesavulu MM, Apparao C. Antihyperglycemic activity of Momordica cymbalaria in alloxan diabetic rats. J Ethnopharmacol 2001;78:67â€“71.
29. Koneri RB, Samaddar S, Simi SM, Rao ST. Neuroprotective effect of a triterpenoid saponin isolated from Momordica cymbalaria Fenzl in diabetic peripheral neuropathy. Indian J Pharmacol 2014;46:76-81.
30. Tomlinson DR, Gardiner NJ. Glucose neurotoxicity. Nat Rev Neurosci 2008;9:36-45.
31. Sango K, Suzuki T, Yanagisawa H, Takaku S, Hirooka H, Tamura M. High glucose-induced activation of the polyol pathway and changes of gene expression profiles in immortalized adult mouse Schwann cells IMS32. J Neurochem 2006;98:446â€“58.
32. Greene DA, Winegrad AI. In vitro studies of the substrates for energy production and the effects of insulin on glucose utilization in the neural components of peripheral nerve. Diabetes 1979;28:878â€“87.
33. Obrosova IG, Fathallah L, Lang HJ, Greene DA. Evaluation of a sorbitol dehydrogenase inhibitor on diabetic peripheral nerve metabolism: a prevention study. Diabetologia 1999;42:1187-94.
34. Sima AA, Sugimoto K. Experimental diabetic neuropathy: an update. Diabetologia 1999;42:773â€“88.
35. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010;106:1319-31.
36. Vague P, Dufayet D, Coste T, Moriscot C, Jannot MF, Raccah D. Association of diabetic neuropathy with Na/K-ATPase gene polymorphism. Diabetologia 1997;40:506â€“11.
37. Nagilla B, Reddy PK. Neuroprotective and antinociceptive effect of curcumin in diabetic neuropathy in rats. Int J Pharm Pharm Sci 2014;6:131-8.
38. Singh R, Kishore L, Kaur N. Diabetic peripheral neuropathy: current perspective and future directions. Pharmacol Res 2014;80:21â€“35.
39. Vlassara H, Cai W, Crandall J. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002;99: 15596â€“601.
40. Ramesh G, MacLean AG, Philipp MT. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflammation 2013:1-20. Doi.org/10.1155/2013/480739. [Article in Press]